Estratest
Result: $16.5 million settlement
Year: 2010
Yarrington v. Solvay Pharmaceuticals, Inc.
In March 2010, the Court granted final approval to a $16.5 million settlement of a false advertising class action lawsuit against Solvay Pharmaceuticals. Lieff Cabraser served as Co-Lead Counsel, representing purchasers of Estratest – a hormone replacement drug.
The complaint alleged that Solvay deceptively marketed Estratest as an FDA-approved drug when in fact Estratest was not approved by the FDA. The settlement provided refunds to consumers for up to 30% of the purchase price paid for Estratest. In addition, $8 million of the settlement was allocated to fund programs and activities related to women’s health concerns at medical schools throughout the nation.
Civil Litigation News
Douglas Cuthbertson to Discuss “Consumer Data Privacy” at Upcoming NASCAT Annual Meeting
Lieff Cabraser partner Douglas Cuthbertson will be a featured speaker at the 2025 NASCAT annual meeting. Doug will be speaking on the
San Francisco Schools Receive Financial Boost From Settlement With JUUL
As reported by the S.F. Chronicle, the San Francisco Unified School District has been awarded a substantial $24.65
Final Approval Granted to Historic $235M Settlement with Altria in National JUUL Youth E-Cigarette Predatory Advertising, Addiction and Injury Litigation
On March 14, 2024, U.S. District Judge William Orrick of the Northern District of California issued an order granting final approval to a comprehensive
